SAN JOSE, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company dedicated to advancing patient care through transformative urology solutions, today announced that Aquablation therapy was assigned a Category I code effective January 1, 2026.
Orthodontists Gather in Brussels and Rome to Explore Advances in Malocclusion Treatment with GS Technology
ROME, July 10, 2025 /PRNewswire/ -- Smartee hosted two European...
SAN DIEGO, July 2, 2025 /PRNewswire/ -- A new prospective study published in BMC Cancer demonstrates that a novel blood-based multi-omics test, SeekInClarity, can accurately...
Dr. Roberta Lotti honoured for a pioneering work on PC111, reinforcing Scinai's strategic option agreement to acquire the Italian biotech company Pincell srl.
JERUSALEM, June 26,...
SHANGHAI, June 25, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that...
HONG KONG, June 15, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") presented the subgroup analysis data from the Phase III COMPASSION-16...
NEWARK, Del., June 5, 2025 /PRNewswire/ --
China's influential innovative drug asset cooperation platform
BIOSeedin Innovation Partnering Conference (BIOS), established in 2021, has quickly become one...